
Article:
Rejeski, K., Subklewe, M. orcid.org/0000-0003-3905-0251, Aljurf, M. et al. (34 more authors) (2023) Immune effector cell-associated hematotoxicity (ICAHT): EHA/EBMT consensus grading and best practice recommendations. Blood Journal. 2023020578. ISSN 0006-4971

https://doi.org/10.1182/blood.2023020578

---

blood

American Society of Hematology
2021 L Street NW, Suite 900,
Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
editorial@hematology.org

Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations

Tracking no: BLD-2023-020578R1

Kai Rejeski (University Hospital, LMU Munich, Germany) Marion Subklewe (University Hospital, LMU Munich, Germany) Mahmoud Aljurf (King Faisal Specialist Hospital, Saudi Arabia) Emmanuel Bachy (Hospices Civils de Lyon, France) Adriana Balduzzi (Università degli Studi di Milano Bicocca, Italy) Pere Barba (Hospital Vall d'Hebron, Spain) Benedetto Bruno (A.O.U. Città della Salute e della Scienza di Torino,SSD Trapianto Allogenico di Cellule Staminali, Italy) Reuben Benjamin (King's College Hospital, United Kingdom) Matteo Carrabba (San Raffaele Scientific Institute, Italy) Christian Chabannon (Institut Paoli-Calmettes, France) Fabio Ciceri (San Raffaele Scientific Institute, Italy) Paolo Corradini (University of Milan, Italy) Julio Delgado (University of Barcelona, Spain) Roberta Di Blasi (Assistance Publique - Hopitaux de Paris, France) Raffaella Greco (San Raffaele Scientific Institute, Italy) Roch Houot (CHU Rennes, France) Gloria Iacoboni (Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain, Spain) Ulrich Jaeger (Medical University of Vienna, Austria) Marie José Kersten (Amsterdam UMC, Netherlands) Stephan Mielke (Karolinska Institute & University Hospital, Sweden) Arnon Nagler (Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel, Israel) Francesco Onida (Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico - University of Milan, Italy) Zinaida Peric (University Hospital Centre Zagreb, Croatia) Claire Roddie (UCL, United Kingdom) Annalisa Ruggeri (San Raffaele Scientific Institute, Italy) Fermin Sanchez-Guijo (Hospital Universitario de Salamanca, Spain) Isabel Sánchez-Ortega (EBMT, Executive Office, Spain) Dominik Schneidawind (University Hospital Zurich, Switzerland) Maria-Luisa Schubert (Heidelberg University Hospital,) John Snowden (Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom) Catherine Thieblemont (AP-HP, Hôpital Saint-Louis, Hemato-oncologie, DMU DHI,F-75010 Paris, France, France) Max Topp (Universitätsklinikum Würzburg, Germany) Pier Luigi Zinzani (University of Bologna, Italy) John Gribben (Barts Cancer Institute, United Kingdom) Chiara Bonini (Università Vita-Salute San Raffaele, Italy) Anna Sureda Balari (Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Spain) Ibrahim Yakoub-Agha (CHU de Lille, France)

Abstract:
Hematological toxicity represents the most common adverse event following chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound, long-lasting, and can predispose for severe infectious complications. In a recent worldwide survey, we demonstrated that there remains considerable heterogeneity in regards to current practice patterns. Here, we sought to build consensus on the grading and management of Immune Effector Cell Associated Hemato-Toxicity (ICAHT) following CAR-T therapy. For this purpose, a joint effort between the European society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) involved an international panel of 36 CAR-T experts who met in a series of virtual conferences, culminating in a 2-day meeting in Lille, France. On the basis of these deliberations, best practice recommendations were developed. For the grading of ICAHT, a classification system based on depth and duration of neutropenia was developed for early (day 0-30) and late cytopenia (after day +30). Detailed recommendations on risk factors, available pre-infusion scoring systems (e.g. CAR-HEMATOTOX score), and diagnostic work-up are provided. A further section focuses on identifying hemophagocytosis in the context of severe hematotoxicity. Finally, we review current evidence and provide consensus recommendations for the management of ICAHT, including growth factor support, anti-infectious prophylaxis, transfusions, autologous hematopoietic cell boost, and allogeneic hematopoietic cell transplantation. In conclusion, we propose ICAHT as a novel toxicity category following immune effector cell therapy, provide a framework for its grading, review literature on risk factors, and outline expert recommendations for the diagnostic work-up and short- and long-term management.

Conflict of interest: COI declared - see note

COI notes: K.R. Kite/Gilead: Research Funding and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria M.S. receives industry research support from Amgen, BMS/Celgene, Gilead, Janssen, Miltenyi Biotec, Novartis, Roche, Seattle Genetics and Takeda and serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Pfizer and Takeda. She serves on the speakers' bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche and Takeda. E.B. Honorarium/Advisory Board: Kite/Gilead, BMS/Celgene, Novartis, Pfizer, Incyte, ADC Therapeutics, Roche, Takeda. Personal fees: Kite/Gilead, BMS/Celgene, Novartis, Pfizer. Research funding: Amgen, BMS. A.B. Speaker's bureau from Novartis, Amgen, Medac; meeting support from Novartis, Amgen, Medac, Neovii P.B. Honoraria and travel support from Allogene, Amgen, BMS, Kit/Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar, Novartis and Pierre Fabre R.B. Research funding from Servier and Allogene. Participated in advisory boards for BMS/Celgene, Janssen, Allogene, Takeda, Enara Bio, Securabio, Menarini Stemline, Arovella, Kite/Gilead M.C. Consultancy: Novartis, Janssen. C.C. Consultant advisor: Bellicum Pharmaceuticals, BMS, Kite/Gilead, Janssen Pharmaceuticals, Novartis. Speaker's bureau: BMS, Kite/Gilead, Janssen Pharmaceuticals, Jazz, Miltenyi Biotec, Novartis. Travel support: BMS, Kite/Gilead P.C. Honoraria: Abbvie, Amgen, Celgene, Daiichi Sankyo, Janssen, Kite/Gilead, Novartis, Roche, Sanofi, Servier, Takeda (Consulting, Advisory role or Lecturer); travel and accommodations paid by for-profit health care companies during the past 2 years: Novartis, Janssen, BMS/Celgene, Takeda, Kite/Gilead, Roche R.D. Novartis: Scientific Advisory Board and Conference speaker. Kite/Gilead: Scientific Advisory Board, Conference speaker, Travel accommodation. Janssen: Scientific Advisory Board. Pfizer: Conference speaker. BMS/Celgene: Scientific Advisory Board. Abbvie : Conference speaker. Incyte : Conference speaker R.G. discloses speaking honoraria from Biotest, Pfizer, Medac, and Magenta.RH: R.H. honoraria from Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche; and consultancy at Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, ADC Therapeutics, Incyte, Miltenyi. G.I. Honoraria: BMS/Celgene, Novartis, Janssen, AstraZeneca, Abbvie, Miltenyi, Roche. U.J. received honoraria and research funding from AbbVie, Bristol Myers Squibb/Celgene, Gilead, Janssen, Novartis, Roche, Sandoz, and Sanofi M.J.K. honoraria from and consulting/advisory role for Bristol Myers Squibb, Celgene, Kite, a Gilead Company, Miltenyi Biotech, Novartis, and Roche; research funding from Kite, Roche, Takeda, and Celgene; and travel support from Kite, Miltenyi Biotech, Novartis, and Roche. S.M. Via Institution: Celgene/BMS: Speaker's bureau; Novartis: Speaker's bureau; Janssen: Speaker's bureau; Gilead/KITE: Travel support, Expert panel; Miltenyi: Data safety monitoring board; Immunicum/Mendes: Data safety monitoring board; SWECARNET: Founder/Leadership; ScientifyResearch: Founder (spouse). F.O. Travel, Accommodations, Expenses: Takeda, Kyowa Kirin International, Medac C.R. Honoraria BMS, Kite/Gilead, Novartis, Amgen F.S.G. Research support from Novartis, Gilead. Honorary from Novartis, Gilead, Pfizer, BMS-Celgene, D.S. Advisory Board with Autolus M.L.S. Advisory board / consultancy: Novartis, Kite-Gilead, Takeda, Janssen; Honoraria: Kite/Gilead J.S. received speaker fees from Gilead and consultancy from Kiadis, Medac and Vertex. C.T. Board with Novartis, Kite/Gilead, BMS, Roche, Takeda, Incyte, Beigene MT: Ad Board: KITE/Gilead, BMS, Janssen, Novartis, Roche, Incyte, Astra Zeneca. Research funding: KITE/Gilead, Takeda, Incyte, Roche, Regeneron P.L.Z. Consultancy: MSD, Eusapharma, Novartis; Advisory Board: Securia Bio, Celltrion, Kite/Gilead, Janssen, BMS/Celgene, Servier, Sandoz, MSD, AstraZeneca, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, ADC therap., Incyte, Belgene. Speakers' Bureau: Celltrion, Kite/Gilead, Janssen, BMS/Celgene, Servier, MSD, AstraZeneca, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, Incyte, Belgene. J.G.G. Received honoraria from Amgen, BMS Gilead/Kite, Janssen, Novartis, and received research funding from AZ, BMS and Janssen. C.B. inventor of different patents on cancer immunotherapy and genetic engineering; member of Advisory Boards and Consultant for, Intellia, Kite/Gilead, Miltenyi, Kiadis, QuellTx, Janssen, Chroma, Genyo, Pancancer-T, Alia, and received research support from Intellia Therapeutics. A.S. Honoraria: Takeda, Bristol Myers Squibb, Merck Sharp & Dohme, Celgene, Janssen, Sanofi, Roche, Novartis, Gilead Sciences, Janssen-Cilag; Consulting or Advisory Role: Takeda, Bristol Myers Squibb, Gilead Sciences, Celgene, Janssen, Novartis; Speakers' Bureau: Takeda; Travel, Accommodations, Expenses: Kite/Gilead I.Y-A. Recived honoraria from Novartis, Gilead/Kite, BMS and Janssen. The remaining authors have nothing to declare. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.

Preprint server: No;

Author contributions and disclosures: Conceptualization: KR, MS; Investigation: KR, MS, MA, EB, AB, PB, BB, RB, MGC, CC, FC, PC, JD, RDB, RG, RH, GI, UJ, MJK, SM, AN, FO, ZP, CR, AR, FSG, ISO, DS, MLS, JAS, CT, MT, PLZ, JGG, CB, AS, IYA; Formal Analysis and Visualization: KR, MS, RG, RH, MJK, SM, CR, FSG, DS, MLS, CT, AS, IYA Methodology: KR, MS, ISO, AS, IYA Writing Original Draft: KR, MS Writing Review and Editing: KR, MS, MA, EB, AB, PB, BB, RB, MGC, CC, FC, PC, JD, RDB, RG, RH, GI, UJ, MJK, SM, AN, FO, ZP, CR, AR, FSG, ISO, DS, MLS, JAS, CT, MT, PLZ, JGG, CB, AS, IYA All authors read and approved the final manuscript.

Non-author contributions and disclosures: No;

Agreement to Share Publication-Related Data and Data Sharing Statement:

Clinical trial registration information (if any):

Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations

Kai Rejeski*[1], Marion Subklewe*[1], Mahmoud Aljurf[2], Emmanuel Bachy[3], Adriana Balduzzi[4], Pere Barba[5], Benedetto Bruno[6], Reuben Benjamin[7], Matteo G. Carrabba[8], Christian Chabannon[9], Fabio Ciceri[8], Paolo Corradini[10], Julio Delgado[11], Roberta Di Blasi[12], Raffaella Greco[8], Roch Houot[13], Gloria Iacoboni[5], Ulrich Jäger[14], Marie José Kersten[15], Stephan Mielke[16], Arnon Nagler[17], Francesco Onida[18], Zinaida Peric[19], Claire Roddie[20], Annalisa Ruggeri[8], Fermín Sánchez-Guijo[21], Isabel Sánchez-Ortega[22], Dominik Schneidawind[23], Maria-Luisa Schubert[24], John A. Snowden[25], Catherine Thieblemont[12], Max Topp[26], Pier-Luigi Zinzani[27], John G. Gribben[28], Chiara Bonini[29], Anna Sureda[30], Ibrahim Yakoub-Agha[31]

* Participated equally to this work

1-Department of Medicine III – Hematology/Oncology, University Hospital, Ludwig-Maximilians- University, Munich, Germany
2-Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3-Department of Hematology, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, France
4- Pediatric Transplantation Unit, Department of Medicine and Surgery, University of Milano-Bicocca - Fondazione IRCCS San Gerardo dei Tintori
5- Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra
6-Division of Hematology and Cell Therapy Unit, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
7- School of Cancer & Pharmaceutical Sciences, King's College London
8- Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
9- Institut Paoli-Calmettes Comprehensive Cancer Centre & module Biothérapies du Centre d'Investigations Cliniques de Marseille, Inserm – Aic-Marseille Université – AP-HM – IPC, CBT-1409
10- Division of Hematology & Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano
11- Oncoimmunotherapy Unit, Department of Hematology, Hospital Clinic de Barcelona, University of Barcelona, FCRB-IDIBAPS, Barcelona, Spain
12- Université de Paris ; Assistance Publique – Hopitaux de Paris, Service d'hémato-oncologie, DMU DHI, Paris, France
13- Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France
14- Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna, Austria
15- Department of Hematology, Amsterdam University Medical Centers, location University of Amsterdam, Cancer Center Amsterdam, Amsterdam, LYMMCARE, the Netherlands
16- Department of Cellular Therapy and Allogenic Stem Cell Transplantation (CAST), Department of Laboratory Medicine and Medicine Huddinge, Karolinska University Hospital and Institutet, Karolinska Comprehensive Cancer Center, Stockholm, Sweden
17- Division of Hematology and CBB, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.
18- Hematology and BMT Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
19- Department of Hematology, University Hospital Centre Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia.
20-University College London Cancer Institute, London, UK; Department of Hematology, University College London Hospital, London, UK.
21-University of Salamanca, IBSAL-University Hospital of Salamanca, Salamanca, Spain
22-EBMT, Executive Office, Barcelona, Spain
23-University Hospital Zurich, Department of Medical Oncology and Hematology, Zurich, Switzerland
24-Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany

25-Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust & Department of Oncology and Metabolism, University of Sheffield, United Kingdom.
26-Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
27-IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
28-Barts Cancer Institute, Queen Mary, University of London, London UK
29-Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Disease, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
30-Clinical Hematology Department, Institut Català d'Oncologia-L'Hospitalet, Barcelona. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona (UB), Spain
31-CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000 Lille, France

Corresponding authors:

Marion Subklewe, M.D.

LMU – Klinikum der Universität München

Department of Hematology & Oncology

Marchioninistrasse 15, 81377 München, Germany

Email: marion.subklewe@med.uni-muenchen.de

Prof. Ibrahim Yakoub-Agha, M.D, P.H.D

UAM allogreffes de CSH, CHRU, F-59037 Lille CEDEX, France

Tel: +33(0)3.20.44.55.51

Email: ibrahim.yakoubagha@chu-lille.fr

Running head: Hematotoxicity following CAR T-cell therapy

Keywords: immune effector cell-associated hematotoxicity, ICAHT, growth factors, hematopoietic cell boost, chimeric antigen receptor (CAR) T-cell therapy

Abstract

Hematological toxicity represents the most common adverse event following chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound, long-lasting, and can predispose for severe infectious complications. In a recent worldwide survey, we demonstrated that there remains considerable heterogeneity in regards to current practice patterns. Here, we sought to build consensus on the grading and management of Immune Effector Cell Associated Hemato-Toxicity (ICAHT) following CAR-T therapy. For this purpose, a joint effort between the European society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) involved an international panel of 36 CAR-T experts who met in a series of virtual conferences, culminating in a 2-day meeting in Lille, France. On the basis of these deliberations, best practice recommendations were developed. For the grading of ICAHT, a classification system based on depth and duration of neutropenia was developed for early (day 0-30) and late cytopenia (after day +30). Detailed recommendations on risk factors, available pre-infusion scoring systems (e.g. CAR-HEMATOTOX score), and diagnostic work-up are provided. A further section focuses on identifying hemophagocytosis in the context of severe hematotoxicity. Finally, we review current evidence and provide consensus recommendations for the management of ICAHT, including growth factor support, anti-infectious prophylaxis, transfusions, autologous hematopoietic cell boost, and allogeneic hematopoietic cell transplantation. In conclusion, we propose ICAHT as a novel toxicity category following immune effector cell therapy, provide a framework for its grading, review literature on risk factors, and outline expert recommendations for the diagnostic work-up and short- and long-term management.

Introduction and state-of-the-art

The last decade has firmly established chimeric antigen receptor (CAR) T-cell therapy as a practice-changing immunotherapy platform for an increasing number of refractory B-cell malignancies.[1-7] While durable remissions can be achieved, this comes with the caveat of a unique spectrum of side effects ranging from Cytokine Release Syndrome (CRS), to Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS), and Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).[8-11] Real-world evidence has underlined the growing importance of hematological toxicity as the most frequent Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 adverse event following CAR T-cell therapy.[12-14] Similarly high rates of cytopenias have been reported for other T-cell based immunotherapies such as bispecific antibodies.[15-19] Notably, profound and often long-lasting cytopenias can add to the immunosuppression conferred by B-cell aplasia and consecutive hypogammaglobulinemia.[20] Importantly, severe infections are a major driver of both morbidity and non-relapse mortality (NRM) following CAR T-cell therapies.[21-23]

Hematological side effects have been described after CAR T-cell therapy regardless of the target antigen (e.g., CD19 vs. CD22 vs. BCMA) and across various disease entities (e.g., LBCL, BCP-ALL, MCL, MM, FL).[3-5,24-29] Several features underline the unique nature of CAR-T related hematotoxicity. First, cytopenias can persist long after the resolution of clinical CRS, and have been reported as long as months to years following CAR T-cell infuson.[30] Hematopoietic count recovery often follows a biphasic trajectory, with intermittent recovery followed by second, or multiple, dips.[12,13] Second, patients can develop very severe bone marrow (BM) aplasia that is often refractory to therapeutic measures such as growth factor support.[13,31,32] Finally, the underlying pathophysiology remains to be elucidated, although recent evidence points towards the importance of both baseline hematopoietic reserve and the systemic inflammatory state of the host.[13] Moreover, the inflammatory stress conferred by severe CRS and the associated alterations in cytokine patterns can exert myelosuppressive effects.[33-35]

In a recent international survey led by EHA and EBMT, we identified a high degree of heterogeneity both in regards to the grading and management of cytopenias.[36] Current grading

systems such as the CTCAE describe cytopenias predominantly in quantitative terms by assigning severity grades according to the depth of cytopenia. However, they are difficult to apply in daily practice and fail to capture the distinct nature of post-CAR-T hematopoietic reconstitution, such as the biphasic and/or delayed course. Furthermore, the cumulative risk of secondary complications (e.g., infections, bleeding) primarily increases with the respective duration of observed cytopenia.[22,37] Classification systems that were developed for cytopenia following classic cytotoxic chemotherapies may not apply to patients receiving novel T-cell based immunotherapies. To accommodate these unique features of hematological side effects in adult patients receiving such therapies, we herein introduce the concept of Immune Effector Cell Associated Hemato-Toxicity, or ICAHT. Based on a novel framework for grading, we outline expert recommendations for its diagnostic work-up and management.

Methodology

This workshop is based on the EBMT PH & G committee method.[38] In September 2022, KR and MS proposed to set up a workshop to issue European recommendations regarding the grading and management of ICAHT, particularly following autologous CAR T-cell therapy. As a first step, an international survey on current practices at >50 global CAR-T centers was sent out and results were analyzed.[36] Experts from different countries and belonging to EBMT and EHA were subsequently invited to join the workshop. As a second step, several teleconferences took place to discuss and advance the first draft. Along with the results of the international survey, a comprehensive literature review was carried out by the workshop participants within each subgroup, which served as the basis for the discussions. The third step consisted of a two-day face-to-face meeting which took place in Lille, France on March 2nd and 3rd, 2023.

These recommendations are intended to be general in scope and applicable to all diseases and types of autologous CAR T-cell therapies or other T-cell based immunotherapies (e.g., bispecific antibody constructs) adopted as standard clinical practice. They are intended to reflect current best practices in this new and rapidly evolving field and aim to help clinicians and other healthcare professionals in providing consistent, high-quality patient care. These recommendations were created due to the growing number of autologous CAR T-cell therapies

currently available outside clinical trials for the treatment of hematological malignancies. Given the lack of high-quality evidence from randomized trials in this area (expected Evidence Levels 3-5, Oxford Centre for Evidence Based Medicine), the decision was made not to grade these recommendations. They therefore represent the consensus point of view of the authors. When administering CAR T-cell therapies within clinical trials, physicians are advised to follow respective trial protocols.

Consensus recommendations

1. ICAHT Grading

On the basis of the results of the international survey on behalf of EHA and EBMT, the expert panel defined early ICAHT as cytopenia occurring during the first 30 days after CAR T-cell infusion. Conversely, late ICAHT was classified as cytopenia observed beyond day +30. The expert panel resolved that the main clinical action points of post-CAR-T cytopenias concerned profound and/or prolonged neutropenia, and that isolated thrombocytopenia or anemia represent rare occurrences. Concomitantly, a grading system based on neutropenia was pursued. For early ICAHT (day 0-30), a grading system based on both depth and duration of neutropenia was defined due to the associated clinical sequelae (**Table 1**, top). Late ICAHT was graded based on the elapsed time from CAR T-cell infusion (e.g., occurring after day +30) with the severity (grade I-IV) defined by the depth of neutropenia (**Table 1**, bottom). For anemia and thrombocytopenia, the expert panel refers to existing grading systems and recommends that institutional guidelines should be followed, as further outlined in **Section 6** and **Table 4** (see *transfusions*).

2. Risk factors for developing post-CAR-T cytopenias

The overall incidence of hematological toxicity in the key registrational trials for CAR T-cell products endorsed by the European Medicines Agency (EMA) are outlined in the **Supplemental Table 1**. Furthermore, we performed an extensive literature review of prominent real-world studies with a specific focus on correlative studies and potential risk factors (**Supplemental Table 2**). Overall, a plethora of factors contribute to the development of cytopenias after CAR-T, some of which remain incompletely understood. Broadly, they relate to the underlying disease and its previous treatments, baseline risk factors (e.g., hematopoietic reserve, BM infiltration,

systemic inflammation), as well as CAR-T product features and CRS-related inflammatory patterns (summarized in **Table 2** and the **Supplementary Text**).[12,13,23,30,33,34,39-56]

3. What scoring systems to use

Based on several of the risk factors delineated above, the CAR-HEMATOTOX score was developed to identify patients at high risk for prolonged neutropenia, and especially the development of the aplastic phenotype of neutrophil recovery.[13] An online calculator can be found on the website of the German Lymphoma Alliance (GLA): https://www.german-lymphoma-alliance.de/Scores.html). The score incorporates factors related to hematopoietic reserve (absolute neutrophil count [ANC], hemoglobin, platelet count) and baseline inflammatory state (CRP, ferritin) and was validated for a primary endpoint of severe neutropenia (ANC <500/µL) lasting longer than 14 days during the first 60 days after CAR-T infusion. Importantly, the CAR-HEMATOTOX score is determined prior to lymphodepleting chemotherapy and thus enables early risk-stratification into a high vs. low risk of developing severe hematotoxicity after CAR T-cell treatment (**Figure 1**). In subsequent studies, the score also identified patients at risk for severe infections and poor treatment outcomes across multiple disease entities (e.g., LBCL, MCL, MM).[22,42-44,57] However, it is important to note that the score remains to be validated prospectively and for adult and pediatric BCP-ALL patients. Furthermore, the test characteristics (high sensitivity, lower specificity) indicate a lower positive predictive value, meaning that not all patients deemed high-risk will develop severe hematotoxicity. Conversely, the high negative predictive value suggests that the score is particularly helpful in ruling out patients at risk for severe hematotoxicity.

4. Assessment and diagnostic work-up of ICAHT

In patients with a high-risk profile for developing ICAHT (**Table 2, Figure 1**), baseline BM studies (prior to apheresis or lymphodepletion) should be considered to risk-stratify patients for hematological toxicity and identify underlying marrow infiltration as a pertinent risk factor. Cryopreservation of the BM aspirate and/or peripheral blood mononuclear cells (PBMCs) is optional, but may provide useful information in case the patient develops secondary BM failure (e.g., presence of CHiP clone).

In case of cytopenia that persists beyond the expected reconstitution of lymphodepleting chemotherapy (typically following week 2-3 after CAR-T infusion), the first step in the work-up comprises defining the differential diagnosis, which can include drug-induced cytopenia, vitamin deficiencies, infectious causes, sustained inflammatory stressors, relapse and/or active BM disease. The expert panel recommends performing an incremental diagnostic-work-up, with an initial tier 1 assessment comprising standard diagnostic tests that should be performed in all cases of severe, or grade ≥III, ICAHT (**Figure 2**). In case the tier 1 results are inconclusive and cytopenias persist and/or are G-CSF refractory (absence of count recovery despite ≥5 days of G-CSF support), a subsequent tier 2 diagnostic work-up can be pursued. Importantly, this includes extended viral studies, as well as BM aspiration and biopsy. The expert panel would reserve cytogenetics and next-generation sequencing to rule out an underlying myeloid malignancy to either cases of profound, long-lasting marrow aplasia (e.g., no count recovery above an ANC ≥500/µL by day +30, pancytopenia), or new-onset pancytopenia that is refractory to therapeutic measures late after CAR-T infusion.

5. Hemophagocytosis associated with severe hematotoxicity after CAR T-cell therapy

Hemophagocytic lymphohistiocytosis (HLH) represents a hyper-inflammatory condition resulting from abnormal immune activation, which is associated with high fever, hyperferritinemia, prolonged cytopenia and eventually multi-organ failure. HLH remains a diagnostic quandary as unique biomarkers are still lacking and/or not readily available. In the context of CAR T-cell therapy, the incidence of HLH-like symptoms ranges from 1% to 3.4%.[10,58] Two entities, CRS/MAS and IEC-HS, can be distinguished according to time of onset and presence of concomitant CRS/ICANS symptoms.[29,59-61] In patients with severe ICAHT that present with aplastic neutrophil recovery and rising serum ferritin, the diagnosis of HLH should be considered, as both can present with profound immune dysregulation and increased IFN signaling.[42,54] A comprehensive work-up is recommended in order to identify additional abnormalities such as new-onset hepatosplenomegaly, hypertriglyceridemia, coagulopathy and hypofibrinogenemia, as well as hemophagocytosis features on BM biopsy or in other tissues (**Fig. 2**). Existing scoring systems that can guide the diagnosis of HLH in

the context of severe ICAHT include HLH-2004 criteria, the H-score, and the OHI index.[62-64] Additionally, **Table S3** outlines the MD Anderson criteria[58], EBMT/EHA/JACIE recommendations[59] and IEC-HS criteria[60], which were deemed more specific to CAR-T therapy by the expert panel. In patients in whom ICAHT manifests in the form of HLH, anti-inflammatory measures should be promptly initiated to mitigate cytokine storm and its clinical sequelae. Patients should be treated with anakinra, a recombinant humanized IL-1 receptor antagonist, in combination with high-dose corticosteroids (**Figure S1**). In refractory cases, ruxolitinib, cytokine adsorption, and emapalumab (IFN-γ inhibitor) can be considered, albeit data remains scarce.[65-67]

6. Management of cytopenias

The management of ICAHT can broadly be separated into an initial phase which addresses the (expected) early cytopenias and aims to mitigate the risk of infections and/other complications, as well as a later phase that is initiated in case of persistent and/or therapy-refractory cytopenias. An overview of the expert recommendations for early ICAHT management if provided in **Table 3**.

Transfusions

Due to the frequent nature of severe anemia and thrombocytopenia after CAR-T therapy, transfusions are an essential part of supportive care and include either packed red blood cell concentrates (pRBCs) or platelet concentrates (PCs). Transfusion-associated GvHD (ta-GvHD) is a rare complication of transfusion wherein viable donor T lymphocytes in cellular blood products mount an immune response against the recipient.[68] Considering the high mortality rate (>90%), prevention of ta-GvHD is recommended, though there is no internationally agreed upon consensus on the duration of the use of irradiated blood products across cellular therapies. In the setting of HCT, standard practice is to use irradiated blood for (1) at least 2 weeks prior to stem cell collection until at least 3 months after auto-HCT, and (2) starting with conditioning at the latest until at least 6 months after allo-HCT, or until immune reconstitution.[69] In the context of CAR-T therapy, the expert panel recommended the irradiation of blood products from 7 days prior to leukapheresis until at least 90 days post-CAR-T infusion unless conditioning, disease or

previous treatment determine indefinite duration (**Table 3**). Of note, the use of the purine analogue fludarabine as a component of lymphodepletion prior to CAR-T infusion may impact local guidance for irradiated blood products.[69] Given its relative rarity, we recommend reporting cases of ta-GVHD following CAR-T to regulatory authorities.

Growth factor support

Granulocyte-macrophage colony-stimulating factor (GM-CSF)

GM-CSF is typically elevated in CAR-T patients with CRS and ICANS. The use of GM-CSF as a growth factor for patients with low blood counts should be avoided as it may promote inflammatory toxicity and induce neuroinflammation following CAR-T therapy.[70,71]

Granulocyte colony-stimulating factor (G-CSF)

Due to the concerns for the use of GM-CSF and the hypothesized, but largely unknown risks of exacerbating toxicities, early guidance suggested generally deferring G-CSF until resolution of acute CAR T-cell related immunotoxicity (typically week 3). However, several recent reports question this as a general rule and point towards an acceptable safety profile for the early use of G-CSF, with no increase of high-grade (≥3°) CRS/ICANS.[72-76] In the largest retrospective analysis by Miller and colleagues (n=197), prophylactic G-CSF *before* CAR-T (mostly pegylated G-CSF) was associated with faster neutrophil recovery, comparable treatment outcomes, and similar rates of severe ICANS.[75] While prophylactic G-CSF was associated with a higher rate of grade ≥2 CRS, this observation did not extend to the clinically relevant grade ≥3 CRS. In a subgroup analysis, the authors found that G-CSF did not worsen severity of CRS in patients who *already* present with low-grade (1°) toxicity. In a further study by Lievin et al, early G-CSF administration (from day +2) in neutropenic patients was associated with a reduced risk of febrile neutropenia without increasing the risk of severe CRS or ICANS.[74] Notably, G-CSF was also safe in maintaining CAR T-cell expansion kinetics and anti-lymphoma activity, without any deleterious impact on the quality of response and outcomes.[73,74] Appraising the above evidence and weighing the benefits and risks, early G-CSF administration on day +2 can be considered in high-risk patients to shorten the length of expected severe neutropenia (see **Table 2** and **Figure 1**). Therapeutic G-CSF in case of prolonged severe neutropenia (ANC <500/µL) can also be

considered, and can be of diagnostic benefit for identifying the aplastic neutrophil recovery phenotype[13,32], which is often G-CSF unresponsive. The large majority of CAR-T patients (>80%) ultimately respond to growth factor support with count recovery.[32,34] However, recurrent neutrophil dips (biphasic course) can necessitate intermittent application of therapeutic G-CSF (**Figure 3**). Finally, a uniform consensus was reached on the necessity of *prospective*, and ideally multicenter, clinical trials that evaluate the safety and optimal treatment protocol for G-CSF (prophylactic vs. early / pegylated vs. non-pegylated) in the context of CAR-T therapy and across disease entities (B-ALL vs. B-NHL vs. MM).

Thrombopoietin (TPO) agonists

TPO agonists (e.g., eltrombopag, romiplostim) are considered primarily in patients with prolonged and late thrombocytopenia, with the thrombocytopenic nadir typically occurring in the 2nd month after CAR-T therapy.[12,13] Data supporting the use of TPO agonists in the CAR-T setting are extremely limited and are restricted to a few case series from single centers with limited patient numbers.[77-79] In these limited reports, improvement in platelets and also hemoglobin and ANC was noted, with some patients becoming transfusion independent both for platelets and pRBCs similar to improvement in hematopoiesis observed with TPO agonist use in cases of acquired BM failure.[80,81] Due to the limited available data, the expert panel advises that the use of TPO agonists should parallel the practice for HCT.[82] They can also be utilized in G-CSF refractory cases of ICAHT (**Figure 3**).

Infection prophylaxis

Regarding the administration of anti-infectious prophylaxis during cytopenia, the expert panel broadly recommends adherence to the general EHA/EBMT/JACIE guidelines for patients receiving CAR T-cell therapy.[59] The following specific recommendations were issued (**Table 3**):

- Adherence to current EHA/EBMT guidelines regarding anti-viral and anti-pneumocystis pneumonia (PCP) prophylaxis, as well as intravenous immunoglobulin (IVIG) substitution for post-CAR-T hypogammaglobulinemia.[59]
- The expert panel does not recommend the use of a neutropenic diet to reduce the risk of infection in neutropenic CAR-T patients.[83-85]

- **Antibacterial prophylaxis**: the panel proposes a risk-adapted strategy based on the patient-individual risk profile for infections including the expected incidence rate of protracted, profound neutropenia (ANC <100/µL for ≥7 days), in line with the consensus American Society of Clinical Oncology (ASCO)/ Infectious Diseases Society of America (IDSA) recommendations for adult cancer patients.[86] Antibacterial prophylaxis with a fluoroquinolone (e.g. levofloxacin, ciprofloxacin) is not recommended in patients who are at a low risk of severe (grade ≥III) ICAHT (**Table 1**, **Table 3**) and should be avoided due to fluoroquinolone-specific side effects, the potential emergence of resistant strains, and selection for *C. difficile* and *enterococci*.[37,87-90] Furthermore, recent publications have demonstrated that antibiotic exposure prior to CAR T-cell therapy reduces microbiome diversity and is associated with inferior outcomes, potentially due to the multifunctional and immunomodulatory role of the gut microbiome.[91-94] On the other hand, antibacterial prophylaxis can be considered in high-risk patients once the ANC falls below <500/µL to mitigate the risk of severe infections. The CAR-HEMATOTOX score may be useful for guidance and identification of high-risk candidates.[13] In a large retrospective analysis of LBCL patients receiving CD19 CAR-T, a significant reduction of severe bacterial infections with fluoroquinolone prophylaxis was observed in CAR-HEMATOTOX^{high} but not CAR-HEMATOTOX^{low} patients, supporting a risk-adapted approach. Importantly, the panel recommends adherence to institutional guidelines that take into account local epidemiology and resistance patterns. In this context, monitoring for multi-drug resistant gram-negative bacteria (MDR GNB) colonization (i.e., active surveillance through rectal swab culture) may be useful both for baseline risk assessment and during prolonged neutropenia.
- **Antifungal prophylaxis:** To reduce the risk of invasive fungal disease (IFD), anti-mold prophylaxis (e.g., micafungin or posaconazole) can be considered in patients at high risk for severe ICAHT (grade ≥III) once the ANC falls below <500/µL (**Table 3**). Additional risk factors to consider are prior allo-HCT, prior invasive aspergillosis and receipt of corticosteroids (either long-term ≥72h or high-dose, e.g., greater than 10 mg of dexamethasone or equivalent). The low overall incidence rate for IFD in the context of CAR-T should be taken into account[95], although fungal infections represent a frequent cause of fatal infectious complications.[22,96] Systemic primary antifungal prophylaxis should

be continued until stable count recovery (ANC >500/µL over 3 days) and discontinuation of steroids for CRS/ICANS management.

Hematopoietic cell boost

Patients who are unresponsive and/or refractory to G-CSF beyond day +14 after CAR-T infusion represent a clinically challenging subgroup of patients at high risk for severe and even fatal infectious complications. While the evidence remains limited, TPO agonists can be offered in this setting, especially in cases of associated thrombocytopenia.[79] In cases of severe ICAHT in which an inflammatory stressor is deemed contributory (severe CRS/ICANS, CRS/MAS), anti-inflammatory strategies such as pulse-dose corticosteroids and/or anti-cytokine therapies (e.g., tocilizumab, anakinra) should be used. A promising strategy pertains to the use of cryopreserved autologous or allogeneic $CD34^+$ hematopoietic cells from prior collection (either prior auto- or allo-HCT).[97-99] Three recent case series shed light on both the safety and clinical feasibility of this approach across a broad population of pediatric and adult patients (summarized in **Supplemental Table 4**). High rates of sustained neutrophil and platelet engraftment were noted across studies. While hematopoietic cell boost (HCB) has been successfully applied during active infection[100], clinicians should be aware of the possibility of immune reconstitution inflammatory syndrome (IRIS) in patients with prolonged bone marrow aplasia.[31] As the earlier application of an *available* HCB was associated with superior survival outcomes,[99] the expert panel recommends considering the application of a HCB without prior conditioning chemotherapy for grade ≥III ICAHT beyond day +14 if (1) a boost is readily available and (2) G-CSF refractoriness has been established. At the same time, the survey results highlighted that even when HCB were considered a viable treatment option in a patient with prior auto-HCT, they were often not available. While prophylactic collection in high-risk candidates has been proposed as a potential mitigating strategy, the panel cautioned that the collection process may add to the already high logistic burden of CAR T-cell therapy (e.g., coordination of apheresis slots and storage capacity), which could negatively impact vein-to-vein times in a state of high disease burden. Furthermore, the process could incur unnecessary collection- and storage-associated costs.[101,102] Ultimately, it was concluded that further research is needed to assess the number needed to treat for prophylactic stem cell collection.

Allogeneic hematopoietic cell transplantation

If the above options remain ineffective or elusive and grade IV ICAHT persists beyond day +30, the expert panel recommends initiating a donor search for a potential allo-HCT as a last resort (ultima ratio). In such cases of life-threatening ICAHT, the benefit and risks of allo-HCT need to be carefully weighed and aligned with the patient's goals-of-care. Furthermore, the possibility of spontaneous count recovery needs to seriously be considered.[34,103,104] Accordingly, the expert panel suggested that the ultimate trigger for allo-HCT needs to be discussed on a case-by-case basis. Month 3-6 post CAR-T infusion was deemed a reasonable time frame to balance both the risk of infection and possibility of spontaneous count recovery. Once the decision for allo-HCT has been made, details regarding donor selection, conditioning regimens and immunosuppression have to be discussed. Experience and evidence are very limited and only general considerations can be reviewed here. As for every allo-HCT, the same basic principles should apply keeping in mind that the primary indication is severe and persistent cytopenia although basically all patients currently receive commercially available CAR-T cells to treat malignant lymphoid disorders. Most importantly, salvage allo-HCT is also capable to provide tumor control through the conditioning regimen and graft-versus-tumor effects and current standard procedures will most likely lead to eradication of CAR-T cells at the latest when full donor chimerism has been established. Therefore, remission status must be determined prior to allo-HCT and may guide the choice of conditioning regimen and the taper of immunosuppression. As usual, performance status, comorbidities, prior therapies and expected anti-tumor activity should be carefully considered when discussing the transplantation modalities, donor choice and selection.

7. Conclusions and Outlook

Much progress has been made in the last years in defining hematological toxicity as a distinct toxicity entity of CAR T-cell therapy. While the underlying pathophysiology remains incompletely understood, growing evidence points towards critical interactions between host hematopoiesis and CAR T-cell function and efficacy. By defining ICAHT and delineating a specific grading

system, we herein provide a nomenclature that enables cross-trial comparisons and invites severity-based management strategies.

In this international consensus guidelines document, we have proposed a structured approach to diagnosis, grading/staging and clinical management of ICAHT. This endeavor has also set the stage for areas of future development that will require collaboration between various European and non-European stakeholders involved in CAR T-cell therapy. Structured sample collection across multiple centers represents the basis for translational projects that delineate the underlying mechanisms of ICAHT by leveraging novel technologies such as multi-omics and single-cell approaches. One area of particular interest lies in identifying early determinants of ICAHT by studying the peripheral blood immune contexture and/or the local BM microenvironment from pre-CAR-T samples. Furthermore, large retrospective real-world analyses may shed light on some of the differences in the clinical management of ICAHT that were identified by the EHA/EBMT survey. Residual questions relate to the optimal timing of G-CSF initiation as well as the optimal protocol to employ (e.g., prophylactic vs. early G-CSF). The question of prophylactic collection of CD34+ hematopoietic cells in high-risk candidates and the optimal trigger time point for both HCB and allo-HCT represent unresolved issues that warrant further systematic study. Ultimately, prospective clinical trials will be needed that determine the potential benefits and evidence-base of treatment strategies that mitigate ICAHT.

Acknowledgements

We are grateful for the support by EHA and EBMT without whom this work would not have been possible.

Competing interests

K.R. Kite/Gilead: Research Funding and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria

M.S. receives industry research support from Amgen, BMS/Celgene, Kite/Gilead, Janssen, Miltenyi Biotec, Novartis, Roche, Seattle Genetics and Takeda and serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Pfizer and Takeda. She serves on the speakers' bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche and Takeda.

E.B. Honorarium/Advisory Board: Kite/Gilead, BMS/Celgene, Novartis, Pfizer, Incyte, ADC Therapeutics, Roche, Takeda. Personal fees: Kite/Gilead, BMS/Celgene, Novartis, Pfizer. Research funding: Amgen, BMS.

A.B. Speaker's bureau from Novartis, Amgen, Medac; meeting support from Novartis, Amgen, Medac, Neovii

P.B. Honoraria and travel support from Allogene, Amgen, BMS, Kit/Gilead, Incyte, Jazz Pharmaceuticals, Miltenyi Biomedicine, Nektar, Novartis and Pierre Fabre

R.B. Research funding from Servier and Allogene. Participated in advisory boards for BMS/Celgene, Janssen, Allogene, Takeda, Enara Bio, Securabio, Menarini Stemline, Arovella, Kite/Gilead

M.C. Consultancy: Novartis, Janssen.

C.C. Consultant advisor: Bellicum Pharmaceuticals, BMS, Kite/Gilead, Janssen Pharmaceuticals, Novartis. Speaker's bureau: BMS, Kite/Gilead, Janssen Pharmaceuticals, Jazz, Miltenyi Biotec, Novartis. Travel support: BMS, Kite/Gilead

P.C. Honoraria: Abbvie, Amgen, Celgene, Daiichi Sankyo, Janssen, Kite/Gilead, Novartis, Roche, Sanofi, Servier, Takeda (Consulting, Advisory role or Lecturer); travel and

399 accommodations paid by for-profit health care companies during the past 2 years: Novartis,
400 Janssen, BMS/Celgene, Takeda, Kite/Gilead, Roche
401 **R.D.** Novartis: Scientific Advisory Board and Conference speaker. Kite/Gilead: Scientific
402 Advisory Board, Conference speaker, Travel accommodation. Janssen: Scientific Advisory
403 Board. Pfizer: Conference speaker. BMS/Celgene: Scientific Advisory Board. Abbvie :
404 Conference speaker. Incyte : Conference speaker
405 **R.G.** discloses speaking honoraria from Biotest, Pfizer, Medac, and Magenta.RH:
406 **R.H.** honoraria from Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche; and
407 consultancy at Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, ADC Therapeutics, Incyte,
408 Miltenyi.
409 **G.I.** Honoraria: BMS/Celgene, Novartis, Janssen, AstraZeneca, Abbvie, Miltenyi, Roche.
410 **U.J.** Consultancy: Novartis, Janssen, Roche; Honoraria: Gilead, BMS/CELGENE, Miltenyi
411 **M.J.K.** honoraria from and consulting/advisory role for Bristol Myers Squibb, Celgene, Kite, a
412 Gilead Company, Miltenyi Biotech, Novartis, and Roche; research funding from Kite, Roche,
413 Takeda, and Celgene; and travel support from Kite, Miltenyi Biotech, Novartis, and Roche.
414 **S.M.** Via Institution: Celgene/BMS: Speaker's bureau; Novartis: Speaker's bureau; Janssen:
415 Speaker's bureau; Gilead/KITE: Travel support, Expert panel; Miltenyi: Data safety monitoring
416 board; Immunicum/Mendes: Data safety monitoring board; SWECARNET: Founder/Leadership;
417 ScientifyResearch: Founder (spouse).
418 **F.O.** Travel, Accommodations, Expenses: Takeda, Kyowa Kirin International, Medac
419 **C.R.** Honoraria BMS, Kite/Gilead, Novartis, Amgen
420 **F.S.G.** Research support from Novartis, Gilead. Honorary from Novartis, Gilead, Pfizer, BMS-
421 Celgene,
422 **D.S.** Advisory Board with Autolus
423 **M.L.S.** Advisory board / consultancy: Novartis, Kite-Gilead, Takeda, Janssen; Honoraria:
424 Kite/Gilead
425 **J.S.** received speaker fees from Gilead and consultancy from Kiadis, Medac and Vertex.
426 **C.T.** Board with Novartis, Kite/Gilead, BMS, Roche, Takeda, Incyte, Beigene
427 MT: Ad Board: KITE/Gilead, BMS, Janssen, Novartis, Roche, Incyte, Astra Zeneca. Research
428 funding: KITE/Gilead, Takeda, Incyte, Roche, Regeneron

P.L.Z. Consultancy: MSD, Eusapharma, Novartis; Advisory Board: Securia Bio, Celltrion, Kite/Gilead, Janssen, BMS/Celgene, Servier, Sandoz, MSD, AstraZeneca, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, ADC therap., Incyte, Belgene. Speakers' Bureau: Celltrion, Kite/Gilead, Janssen, BMS/Celgene, Servier, MSD, AstraZeneca, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, Incyte, Belgene.

J.G.G. Received honoraria from Amgen, BMS Gilead/Kite, Janssen, Novartis, and received research funding from AZ, BMS and Janssen.

C.B. inventor of different patents on cancer immunotherapy and genetic engineering; member of Advisory Boards and Consultant for, Intellia, Kite/Gilead, Miltenyi, Kiadis, QuellTx, Janssen, Chroma, Genyo, Pancancer-T, Alia, and received research support from Intellia Therapeutics.

A.S. Honoraria: Takeda, Bristol Myers Squibb, Merck Sharp & Dohme, Celgene, Janssen, Sanofi, Roche, Novartis, Gilead Sciences, Janssen-Cilag; Consulting or Advisory Role: Takeda, Bristol Myers Squibb, Gilead Sciences, Celgene, Janssen, Novartis; Speakers' Bureau: Takeda; Travel, Accommodations, Expenses: Kite/Gilead

I.Y-A. Recived honoraria from Novartis, Gilead/Kite, BMS and Janssen.

The remaining authors have nothing to declare. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.

Author contributions

Conceptualization: KR, MS;

Investigation: KR, MS, MA, EB, AB, PB, BB, RB, MGC, CC, FC, PC, JD, RDB, RG, RH, GI, UJ, MJK, SM, AN, FO, ZP, CR, AR, FSG, ISO, DS, MLS, JAS, CT, MT, PLZ, JGG, CB, AS, IYA;

Formal Analysis and Visualization: KR, MS, RG, RH, MJK, SM, CR, FSG, DS, MLS, CT, AS, IYA

Methodology: KR, MS, ISO, AS, IYA

Writing Original Draft: KR, MS

Writing Review and Editing: KR, MS, MA, EB, AB, PB, BB, RB, MGC, CC, FC, PC, JD, RDB, RG, RH, GI, UJ, MJK, SM, AN, FO, ZP, CR, AR, FSG, ISO, DS, MLS, JAS, CT, MT, PLZ, JGG, CB, AS, IYA

All authors read and approved the final manuscript.

References

1. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med.* 2022;386(7):640-654.
2. Abramson JS, Solomon SR, Arnason JE, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. *Blood.* 2022.
3. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. *Lancet.* 2021;398(10299):491-502.
4. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med.* 2020;382(14):1331-1342.
5. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. *N Engl J Med.* 2019;380(18):1726-1737.
6. Snowden JA, Sanchez-Ortega I, Corbacioglu S, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. *Bone Marrow Transplant.* 2022;57(8):1217-1239.
7. Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. *Bone Marrow Transplant.* 2021;56(7):1651-1664.
8. Shimabukuro-Vornhagen A, Godel P, Subklewe M, et al. Cytokine release syndrome. *J Immunother Cancer.* 2018;6(1):56.
9. Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. *Blood.* 2019;133(20):2212-2221.
10. Sandler RD, Tattersall RS, Schoemans H, et al. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). *Front Immunol.* 2020;11:524.
11. Hines MR, Knight TE, McNerney KO, et al. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). *Transplant Cell Ther.* 2023.
12. Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. *Bone Marrow Transplant.* 2019;54(10):1643-1650.
13. Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. *Blood.* 2021;138(24):2499-2513.
14. Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. *Blood Adv.* 2020;4(13):3024-3033.
15. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 2022;387(24):2220-2231.
16. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. *J Clin Oncol.* 2022:JCO2201725.
17. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. *N Engl J Med.* 2022;387(24):2232-2244.
18. Moreau P, Girgis S, Goldberg JD. Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply. *N Engl J Med.* 2022;387(18):1722-1723.
19. Goebeler ME, Knop S, Viardot A, et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. *J Clin Oncol.* 2016;34(10):1104-1111.
20. Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. *Blood.* 2020;136(8):925-935.
21. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. *J Clin Oncol.* 2020;38(27):3119-3128.

22. Rejeski K, Perez A, Iacoboni G, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. *J Immunother Cancer.* 2022;10(5).
23. Bethge WA, Martus P, Schmitt M, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. *Blood.* 2022.
24. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet.* 2021;398(10297):314-324.
25. Munshi NC, Anderson LD, Jr., Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *N Engl J Med.* 2021;384(8):705-716.
26. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol.* 2022;23(1):91-103.
27. Iacoboni G, Rejeski K, Villacampa G, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. *Blood Adv.* 2022.
28. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med.* 2018;378(5):439-448.
29. Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. *Blood.* 2021;138(24):2469-2484.
30. Cordeiro A, Bezerra ED, Hirayama AV, et al. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. *Biol Blood Marrow Transplant.* 2020;26(1):26-33.
31. Rejeski K, Kunz WG, Rudelius M, et al. Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report. *BMC Infect Dis.* 2021;21(1):121.
32. Jain T, Olson TS, Locke FL. How I Treat Cytopenias after CAR T-cell Therapy. *Blood.* 2023.
33. Juluri KR, Wu V, Voutsinas JM, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. *Blood Adv.* 2021.
34. Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. *Blood Adv.* 2020;4(15):3776-3787.
35. Rejeski K, Wu Z, Blumenberg V, et al. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T for Richter transformed DLBCL. *Blood.* 2022.
36. Rejeski K, Greco R, Onida F, et al. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA. *Hemasphere.* 2023;7(5):e889.
37. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. *J Clin Oncol.* 2018;36(30):3043-3054.
38. Yakoub-Agha I, Greco R, Onida F, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. *Bone Marrow Transplant.* 2023.
39. Xia Y, Zhang J, Li J, et al. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. *Ann Med.* 2022;54(1):2951-2965.
40. Brudno JN, Natrakul D, Lam N, Dulau-Florea A, Yuan CM, Kochenderfer JN. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. *Leuk Lymphoma.* 2022;63(8):1849-1860.
41. Roddie C, Neill L, Osborne W, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. *Blood Adv.* 2023.
42. Rejeski K, Perez Perez A, Iacoboni G, et al. Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time. *Blood.* 2022;140(Supplement 1):4549-4551.

43. Rejeski K, Wang Y, Albanyan O, et al. The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma. *Blood.* 2022;140(Supplement 1):651-653.
44. Rejeski K, Hansen DK, Bansal R, et al. The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma. *Blood.* 2022;140(Supplement 1):7506-7508.
45. Liu Y, Derkach A, Lewis N, et al. Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm. *Haematologica.* 2023;108(3):917-922.
46. Saini NY, Swoboda DM, Greenbaum U, et al. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. *Blood Cancer Discov.* 2022;3(5):385-393.
47. Miller PG, Sperling AS, Brea EJ, et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. *Blood Adv.* 2021;5(15):2982-2986.
48. Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. *Blood.* 2021;137(19):2621-2633.
49. Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. *Nat Med.* 2022;28(10):2145-2154.
50. Luo W, Li C, Zhang Y, et al. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. *BMC Cancer.* 2022;22(1):98.
51. Kawalekar OU, RS OC, Fraietta JA, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. *Immunity.* 2016;44(3):712.
52. Zhao Z, Condomines M, van der Stegen SJC, et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. *Cancer Cell.* 2015;28(4):415-428.
53. Wang Y, Song Z, Geng Y, et al. The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy. *Front Oncol.* 2022;12:987965.
54. Li X, Deng Q, Henderson J, et al. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. *Blood.* 2022;140(Supplement 1):4502-4503.
55. de Bruin AM, Demirel O, Hooibrink B, Brandts CH, Nolte MA. Interferon-gamma impairs proliferation of hematopoietic stem cells in mice. *Blood.* 2013;121(18):3578-3585.
56. Morales-Mantilla DE, King KY. The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease. *Curr Stem Cell Rep.* 2018;4(3):264-271.
57. Rejeski K, Blumenberg V, Iacoboni G, et al. Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. *Hemasphere.* 2023;7(4):e858.
58. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nat Rev Clin Oncol.* 2018;15(1):47-62.
59. Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). *Ann Oncol.* 2022;33(3):259-275.
60. Hines MR, Knight TE, McNerney KO, et al. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). *Transplantation and Cellular Therapy* 2023.
61. Cutini I, Puccini B, Fabbri A, et al. Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel. *Transpl Immunol.* 2022;75:101719.
62. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer.* 2007;48(2):124-131.
63. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. *Arthritis Rheumatol.* 2014;66(9):2613-2620.

64. Zoref-Lorenz A, Murakami J, Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. *Blood.* 2022;139(7):1098-1110.
65. McNerney KO, DiNofia AM, Teachey DT, Grupp SA, Maude SL. Potential Role of IFNgamma Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. *Blood Cancer Discov.* 2022;3(2):90-94.
66. Rainone M, Ngo D, Baird JH, et al. Interferon-gamma blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis. *Blood Adv.* 2023;7(4):533-536.
67. La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. *Blood.* 2019;133(23):2465-2477.
68. Kopolovic I, Ostro J, Tsubota H, et al. A systematic review of transfusion-associated graft-versus-host disease. *Blood.* 2015;126(3):406-414.
69. Foukaneli T, Kerr P, Bolton-Maggs PHB, et al. Guidelines on the use of irradiated blood components. *Br J Haematol.* 2020;191(5):704-724.
70. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. *Nat Med.* 2018;24(6):731-738.
71. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. *Blood.* 2019;133(7):697-709.
72. Barreto JN, Bansal R, Hathcock MA, et al. The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy. *Am J Hematol.* 2021;96(10):E399-E402.
73. Galli E, Allain V, Di Blasi R, et al. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. *Bone Marrow Transplant.* 2020;55(12):2347-2349.
74. Lievin R, Di Blasi R, Morin F, et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. *Bone Marrow Transplant.* 2022.
75. Miller KC, Johnson PC, Abramson JS, et al. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. *Blood Cancer J.* 2022;12(10):146.
76. Ma S, Li H, Zhou D, et al. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. *Cytotherapy.* 2023.
77. Baur R, Jitschin R, Kharboutli S, et al. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report. *J Immunother Cancer.* 2021;9(7).
78. Beyar-Katz O, Perry C, On YB, et al. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience. *Ann Hematol.* 2022;101(8):1769-1776.
79. Drillet G, Lhomme F, De Guibert S, Manson G, Houot R. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists. *Blood Adv.* 2023;7(4):537-540.
80. Drexler B, Passweg J. Current evidence and the emerging role of eltrombopag in severe aplastic anemia. *Ther Adv Hematol.* 2021;12:2040620721998126.
81. Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. *N Engl J Med.* 2022;386(1):11-23.
82. Bento L, Bastida JM, Garcia-Cadenas I, et al. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. *Biol Blood Marrow Transplant.* 2019;25(9):1825-1831.
83. Ball S, Brown TJ, Das A, Khera R, Khanna S, Gupta A. Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia: A Meta-analysis of Randomized Controlled Trials. *Am J Clin Oncol.* 2019;42(3):270-274.
84. Sonbol MB, Jain T, Firwana B, et al. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. *BMJ Support Palliat Care.* 2019;9(4):425-433.

85. Stella F, Marasco V, Levati GV, et al. Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial. *Blood.* 2022;140(Supplement 1):417-419.
86. Teipel R, Kroschinsky F, Kramer M, et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. *Blood Adv.* 2022;6(6):1941-1946.
87. Spellberg B, Doi Y. The Rise of Fluoroquinolone-Resistant Escherichia coli in the Community: Scarier Than We Thought. *J Infect Dis.* 2015;212(12):1853-1855.
88. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. *Clin Infect Dis.* 2005;41(7):923-929.
89. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. *J Infect.* 2009;58(4):299-307.
90. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. *Curr Opin Infect Dis.* 2011;24(6):545-553.
91. Schubert ML, Rohrbach R, Schmitt M, Stein-Thoeringer CK. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. *Front Immunol.* 2021;12:670286.
92. Blumenberg V, Busch G, Baumann S, et al. High Bacterial Abundances of Dorea and Pediococcus in the Gut Microbiome Linked to Expansion, Immune Checkpoint Expression and Efficacy of CD19-Directed CAR T-Cells in Patients with r/r DLBCL. *Blood.* 2021;138(Supplement 1):2792-2792.
93. Smith M, Dai A, Ghilardi G, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. *Nat Med.* 2022;28(4):713-723.
94. Stein-Thoeringer CK, Saini NY, Zamir E, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. *Nat Med.* 2023.
95. Little JS, Aleissa MM, Beluch K, et al. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. *Blood Adv.* 2022;6(16):4821-4830.
96. Haidar G, Dorritie K, Farah R, Bogdanovich T, Nguyen MH, Samanta P. Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis. *Clin Infect Dis.* 2019.
97. Rejeski K, Burchert A, Iacoboni G, et al. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. *Blood Adv.* 2022;6(16):4719-4725.
98. Mullanfiroze K, Lazareva A, Chu J, et al. CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. *Blood Adv.* 2022;6(16):4715-4718.
99. Gagelmann N, Wulf GG, Duell J, et al. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study. *Blood Adv.* 2023;7(4):555-559.
100. Lipsitt A, Beattie L, Harstead E, et al. Allogeneic CD34(+) selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection. *Pediatr Blood Cancer.* 2023;70(3):e30166.
101. Chhabra S, Thapa B, Szabo A, et al. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. *Biol Blood Marrow Transplant.* 2020;26(11):2011-2017.
102. Liang EC, Muffly LS, Shiraz P, et al. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. *Transplant Cell Ther.* 2021;27(5):405 e401-405 e406.
103. Logue JM, Peres LC, Hashmi H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. *Blood Adv.* 2022;6(24):6109-6119.
104. Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. *Haematologica.* 2020.

105. Alizadeh D, Wong RA, Yang X, et al. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. *Cancer Immunol Res.* 2019;7(5):759-772.
106. Pascutti MF, Erkelens MN, Nolte MA. Impact of Viral Infections on Hematopoiesis: From Beneficial to Detrimental Effects on Bone Marrow Output. *Front Immunol.* 2016;7:364.
107. Porter TJ, Lazarevic A, Ziggas JE, et al. Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. *Br J Haematol.* 2022;199(5):720-727.

Main Tables and Table Legends

Table 1: ICAHT Grading

Grading	I	II	III	IV
Early ICAHT (day 0-30)				
ANC ≤ 500/µL	<7 days	7-13 days	≥14 days	Never above 500/µL
ANC ≤ 100/µL	-	-	≥7 days	≥14 days
*Late ICAHT (after day +30)**				
ANC ≤ 1500/µL				
ANC ≤ 1000/µL				
ANC ≤ 500/µL				
ANC ≤ 100/µL				

*measured ≥2 time points, or non-transient neutropenia

Table 2: Risk factors associated with an increased risk of post-CAR-T cytopenias

	Risk Factors	Comments	References
Disease-related features	Underlying disease (ALL > B-NHL)	Evidence concerning the rate of cytopenias in multiple myeloma patients still emerging	Xia et al.[39]
	Disease burden at CAR-T infusion (progressive disease, high LDH)	Specially BM disease burden	Wudhikarn et al.[14] Logue et al.[103]
Prior therapies	Number of prior therapy lines	Associated with baseline hematopoietic function	Xia et al.[39]
	Prior hematopoietic stem cell transplantation (HSCT)		Fried et al.[105]
	Bridging Therapy		Roddie et al.[41]
Baseline Marrow Status	Bone marrow infiltration		Rejeski et al.[42] Brudno et al.[40]
	Pre-existing cytopenias	Particularly pre-existing thrombocytopenia	Rejeski et al.[13] Juluri et al.[33]
	Clonal hematopoiesis of indeterminate potential (CHiP)?	Has been linked to increased inflammation, potential emerging risk factor	Saini et al.[46] Miller et al.[47] Teipel et al.[86]
Baseline Inflammatory Status	Increased Serum CRP		Rejeski et al.[13]
	Increased Serum Ferritin		Rejeski et al.[13]
CAR-T Product and post-infusion risk factors	Co-stimulatory molecule (CD28>41BB)	May also reflect differences in lymphodepletion dosing (cyclophosphamide dosing)	Xia et al.[39]
	Type of construct (Tandem > single target)		Xia et al.[39]
	Severe CRS		Juluri et al.[33] Jain et al.[34]
	Sustained increased inflammatory markers		Juluri et al.[33]
	Oligoclonal T-cell expansion	In select patients; the success of auto-HCT boost argues against this as a general mechanism	Rejeski et al.[35]
	Active Infection	Mainly viral or in case of concomitant sepsis	Pascutti et al.[106]
	CRS/MAS or IEC-HS	Cytopenia as overlapping symptomology	Sandler et al.[10] Hines et al.[11] Porter et al.[107]

Table 3: Short-term management of cytopenias

	When	How	Precautions	Comments
Packed red bood cell (pRBC)/ Platelet transfusions	As per institutional standards, based on patient risk profile	As per institutional standards For pRBC: consider using 1 product per time to reduce iron overload[69]	Irradiation of blood products; Start 7 days prior to leukapheresis until at least 90 days post CAR-T	Due to the use of fludarabine
G-CSF	**Prophylactic G-CSF:** On day +2 in patients with a high-risk profile for ICAHT (e.g. high CAR-HEMATOTOX score and risk profile according to **Table 2**)	Based on individual risk profile: Consider early G-CSF administration (from day +2) as prophylaxis in high risk for ICAHT Dosing: 5 µg/kg once daily	In patients at low risk for ICAHT, G-CSF probably not necessary*	Reduced risk of febrile neutropenia (without increasing the risk of severe, or grade ≥3, CRS nor ICANS). No detrimental effect on CAR-T expansion kinetics or treatment outcomes[74,75]
	Therapeutic G-CSF: Severe neutropenia (ANC <500/µL) neutropenia with or without infectious complications	In case of prolonged neutropenia with/without infectious complications. Dosing: 5 µg/kg once daily, consider increasing dose in case of non-response		Patients with intermittent neutrophil recovery often rapidly respond to G-CSF stimulation, while aplastic patients are often G-CSF unresponsive
Antibacterial prophylaxis	In patients with a low risk for ICAHT, not recommended. In patients with a high-risk profile for ICAHT, prophylaxis may be considered once ANC <500/µL.	As per institutional standards (e.g. levofloxacin or ciprofloxacin).	Warning in case of colonization by MDR pathogens.	Look at local bacterial epidemiology. High local prevalence of MDR GNB might prevent the use of antibacterial prophylaxis
Anti-viral	All patients	Start from LD conditioning until 1-year post-CAR T-cell infusion AND/OR until CD4+ count >0.2 × 10^9/l Valaciclovir 500 mg bid or aciclovir 800 mg bid		
Anti-pneumocystis	All patients	To start from LD conditioning until 1-year post-CAR-T cell infusion AND/OR until CD4+ count >0.2x10 G/l Co-trimoxazole 480 mg once daily or 960 mg three times each week	In case of co-trimoxazole allergy, pentamidine inhalation (300 mg once every month), dapsone 100 mg daily or atovaquone 1500 mg once daily can be considered	Can be started later depending on center guidelines
Systemic primary anti-fungal prophylaxis	Prophylaxis may be considered in severe neutropenia (ANC <500) with a high-risk profile for ICAHT (e.g. CAR HEMATOTOX score and risk profile according to **Table 2**) and/or prolonged neutropenia	Mold-active prophylaxis for 1-3 months (depending on the duration of neutropenia and use of steroids): posaconazole (300 mg/day) or micafungin (50 mg i.v./day)		In patients with prior allo-HCT, prior invasive aspergillosis and those receiving corticosteroids (long-term >72 h, or high-dose), prophylaxis is recommended

772 **Figure Legends**

773 **Figure 1. The CAR-HEMATOTOX score as a risk-stratification tool**

774

775 **Figure 2. Step-by-step diagnostic work-up depending on ICAHT severity**

776 * In case of elevated ferritin and clinical suspicion of MAS, see **Table S3** and **Figure S1**

777

778 **Figure 3. Treatment algorithm for Immune Effector Cell Associated Neutropenia**

779 *High-risk defined as prior history of hematopoietic stem cell transplantation, baseline cytopenia,
780 high tumor burden and systemic inflammation, presence of BM infiltration.

781 **Anti-fungal prophylaxis particularly recommended in patients with prior IFD, prior allo-HCT, and
782 receiving corticosteroids (long-term >72h or high-dose). Decision for/against anti-bacterial
783 prophylaxis should incorporate local bacterial epidemiology (e.g. prevalence for MDR GNB); not
784 recommended for patients with a low-risk profile for ICAHT

785 † Also extends to late ICAHT if these criteria are met

Figure 1

Prior to lymphodepleting chemotherapy (day -5)

Determine patient-individual risk of heme-tox and infections using the **CAR-HEMATOTOX score**

- Leniency time period for lab values: 3 days

Features	0 Point	1 Point	2 Points
Platelet Count	> 175.000/µl	75.000 - 175.000/µl	< 75.000/µl
Absolute Neutrophil Count (ANC)	> 1200/µl	< 1200/µl	-
Hemoglobin	> 9.0 g/dl	< 9.0 g/dl	-
C-reactive protein (CRP)	< 3.0 mg/dl	> 3.0 mg/dl	-
Ferritin	< 650 ng/ml	650-2000 ng/ml	> 2000 ng/ml
Low: 0-1 **High: ≥ 2**			

Low Risk (HT 0-1)

High Risk (HT 2-7)

Risk Profile

	LBCL (n=235)	MCL (n=103)	MM (n=113)
Median duration of severe neutropenia (ANC<500/µL, D0-60)	5.5 days (95% CI 5-8 days)	6 days (95% CI 5-7 days)	3 days (95% CI 2-5 days)
Aplastic Phenotype	2.6%	0%	3%
Severe Infection Rate	8%	5%	5%
Severe Bacterial Infection Rate	0.9%	5%	3%

	LBCL (n=235)	MCL (n=103)	MM (n=113)
Duration of severe neutropenia (ANC <500/µL day 0-60)	12 days (95% CI 10-16 days)	14 days (95% CI 9-18 days)	9 days (95% CI 7-13 days)
Aplastic Phenotype	36%	47%	32%
Severe Infection Rate	40%	30%	40%
Severe Bacterial Infection Rate	27%	28%	34%

Figure 2

	Categories	Putative causes	Test	Time points	Comments from expert panel
TIER 1	Lower threshold to perform – minimal workup				
	Poor bone marrow reserve	Prior treatments including allo-HCT, fludarabine, marrow infiltration	Complete blood count (CBC), reticulocyte production index (RPI), peripheral blood smear	routinely	Recommended
	Medication – drug side effects	Check for concomitant myelosuppressive medications		routinely	
	Vitamin deficiencies	Vitamin B12, Folic acid	Serum levels	routinely	Recommended
	Rule out infections	Bacterial/ Viral/Fungal infections	Blood cultures, CMV PCR, Procalcitonin $CD4^+$ T-cell, IgG, B-cell levels	routinely	Recommended
	Rule out macrophage-activation syndrome*	CRS/MAS or IEC-HS	Ferritin, triglycerides	routinely	Recommended
TIER 2	Subsequent work-up – In case of G-CSF refractory state, if tier 1 results are negative and/or risk factors are present				
	Viral PCR considering the clinical presentation	Parvovirus	Parvovirus B19 PCR	In case of prolonged anemia	Recommended
		HHV6, JC	HHV6, JC PCR blood/CSF	In case of neurologic symptoms	Recommended
		EBV, adeno, HSV	PCR	In case of HLH	Recommended
	Bone marrow disease	(MDS/AML/myelofibrosis) or relapse	BM aspirate, biopsy, Flow cytometry, immunohistochemistry, cytogenetics, NGS	In case of prolonged cytopenia	Recommended
		Relapse of leukemia/lymphoma	Flow cytometry peripheral blood / bone marrow, With B-cell panel	routinely	Recommended
	Other causes	Other rare hematologic diseases, myeloid diseases, PNH, autoimmune processes	Myeloid panel, PI-linked structures, Direct Antiglobulin Test (DAT)	In case of suspected MPN/PNH/ autoimmune processes	Recommended

Figure 3